Showing 31-40 of 454 results
At Helsinn, our vision is to help people with cancer get the most out of every day. We are committed to making everything we do - from the products we choose to license to the exacting standards we apply as a pharmaceutical manufacturer - count towards the best supportive care for cancer patients.
Helsinn’s extensive network of partners who commercialize the group’s products around the world has been built and constantly expanded over several decades. It represents our strong commitment to bringing to as many patients as possible our comprehensive portfolio of medicines and therapies, aiming at helping to improve the lives of patients.
Helsinn was originally founded as an in-licensing company over 40 years ago. Thanks to this heritage, we have decades of expertise in identifying and sourcing innovative NCEs in the early to late stage of development, then taking them through the full clinical development program and towards registration, commercialization and distribution.
Acute pain is part of an early warning system aimed at minimizing physical harm and avoiding tissue damage from environmental stimuli. Nonsteroidal anti-inflammatory drugs (NSAIDs) play a crucial role in the management of acute inflammatory pain.
Gastroenterology is the branch of Medicine devoted to the study, diagnosis and treatment of disorders of the digestive system. From the anatomical point of view, these disorders may affect the esophagus, stomach, intestines, rectum, liver, gallbladder and pancreas.
Our Integrative Care team was created to focus fully on the development and delivery of high-quality, high-purity, evidence-based products for people with cancer and survivors of the disease.
Lugano, Switzerland, November 18, 2014 – Helsinn Group, the company focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn’s Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Wednesday, 19 November, 2014 at 17:00 GMT. The conference will be held at the Waldorf Hilton Hotel, Aldwych, Lon...
Lugano, Switzerland, November 18, 2014 – Helsinn Group, the company focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn’s Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Wednesday, 19 November, 2014 at 17:00 GMT. The conference will be held at the Waldorf Hilton Hotel, Aldwych, Lon...
Lugano, Switzerland, November 18, 2014 – Helsinn Group, the company focused on building quality cancer care, is pleased to announce that Riccardo Braglia, Helsinn’s Chief Executive Officer, is scheduled to present at the Jefferies 2014 Global Healthcare Conference on Wednesday, 19 November, 2014 at 17:00 GMT. The conference will be held at the Waldorf Hilton Hotel, Aldwych, Lon...